How are you counseling HR-proficient ovarian cancer patients about front line PARP inhibitor maintenance?

I think this is a tough decision, but I recommend observation for patients with HR proficient disease. In brief, I don't find a PFS advantage, without a proven OS advantage, enough to justify this long-term, expensive, and not non-toxic treatment.

For BRCA carriers the answer is easier—with SOLO2 (20...

It’s truly exciting to have new FDA approvals in ovarian cancer. Both the PRIMA trial (González-Martín et al, NEJM 2019) and the PAOLO trial (Ray-Coquard et al NEJM 2019) have led to recent approvals for front-line maintenance therapies. When comparing data for the current front-line maintenance opt...